Syndax Pharmaceuticals 향후 성장

Future 기준 점검 5/6

Syndax Pharmaceuticals은 연간 수입과 매출이 각각 61.9%와 33.8% 증가할 것으로 예상되고 EPS는 연간 61.7%만큼 증가할 것으로 예상됩니다.

핵심 정보

61.9%

이익 성장률

61.75%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	33.8%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	09 Dec 2025

최근 향후 성장 업데이트

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Nov 06

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

May 08

Recent updates

Syndax Pharma: Continuing Execution In AML

Dec 17

Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 23

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Nov 06

Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Aug 06

Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Aug 05

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

May 08

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

이익 및 매출 성장 예측

NasdaqGS:SNDX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	740	126	190	241	6
12/31/2027	564	23	191	89	11
12/31/2026	369	-119	55	-51	12
12/31/2025	168	-266	-259	-154	12
9/30/2025	111	-312	-311	-311	N/A
6/30/2025	78	-335	-303	-303	N/A
3/31/2025	44	-331	-287	-287	N/A
12/31/2024	24	-319	-275	-275	N/A
9/30/2024	16	-297	-259	-259	N/A
6/30/2024	4	-264	-241	-241	N/A
3/31/2024	N/A	-241	-205	-205	N/A
12/31/2023	N/A	-209	-161	-161	N/A
9/30/2023	N/A	-176	-142	-142	N/A
6/30/2023	N/A	-160	-126	-126	N/A
3/31/2023	N/A	-153	-131	-131	N/A
12/31/2022	N/A	-149	-134	-134	N/A
9/30/2022	127	-14	-10	-10	N/A
6/30/2022	139	1	-7	-6	N/A
3/31/2022	139	15	10	10	N/A
12/31/2021	140	25	29	29	N/A
9/30/2021	14	-92	-87	-87	N/A
6/30/2021	2	-91	-81	-81	N/A
3/31/2021	2	-86	-78	-78	N/A
12/31/2020	2	-77	-71	-71	N/A
9/30/2020	2	-71	-68	-68	N/A
6/30/2020	2	-63	-59	-59	N/A
3/31/2020	2	-61	-50	-50	N/A
12/31/2019	2	-56	-51	-51	N/A
9/30/2019	2	-61	-53	-53	N/A
6/30/2019	2	-65	N/A	-63	N/A
3/31/2019	2	-69	N/A	-65	N/A
12/31/2018	2	-74	N/A	-69	N/A
9/30/2018	2	-74	N/A	-66	N/A
6/30/2018	2	-72	N/A	-58	N/A
3/31/2018	2	-67	N/A	-55	N/A
12/31/2017	2	-61	N/A	-47	N/A
9/30/2017	1	-53	N/A	-45	N/A
6/30/2017	1	-52	N/A	-46	N/A
3/31/2017	1	-47	N/A	-41	N/A
12/31/2016	1	-47	N/A	-35	N/A
9/30/2016	1	-45	N/A	-29	N/A
6/30/2016	1	-87	N/A	-23	N/A
3/31/2016	1	-105	N/A	-20	N/A
12/31/2015	1	-104	N/A	-2	N/A
9/30/2015	0	-100	N/A	-2	N/A
6/30/2015	0	-53	N/A	1	N/A

애널리스트 향후 성장 전망

수입 대 저축률: SNDX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.3%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: SNDX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: SNDX 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: SNDX 의 수익(연간 33.8%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: SNDX 의 수익(연간 33.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SNDX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/05 19:58
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Syndax Pharmaceuticals, Inc.는 29명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Peter Lawson	Barclays
Etzer Darout	Barclays
Jason Zemansky	BofA Global Research

Syndax Pharmaceuticals 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Forecast to breakeven in 2027

Price target increased by 11% to US$36.36

Consensus revenue estimates increase by 37%

Consensus revenue estimates increase by 46%

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

Recent updates

Syndax Pharma: Continuing Execution In AML

Syndax Highlights Leadership in Menin Inhibition At Ash 2025 with Multiple Revuforj®? (Revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Syndax Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Syndax Pharmaceuticals Announces FDA Approval of Revuforj®? (Revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Syndax's Revuforj (Revumenib) Included in NCCN Clinical Practice Guidelines in Oncology for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

CEO & Director exercised options and sold US$867k worth of stock

Forecast to breakeven in 2027

Independent Chairman notifies of intention to sell stock

Price target increased by 11% to US$36.36

Consensus revenue estimates increase by 37%

Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Syndax Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 04, 2025

William Meury Resigns from the Board of Directors of Syndax Pharmaceuticals, Inc., Effective June 24, 2025

Syndax Pharmaceuticals Announces FDA Priority Review of sNDA for Revuforj® (Revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

Insider recently bought US$106k worth of stock

New minor risk - Share price stability

Consensus revenue estimates increase by 46%

Syndax Pharmaceuticals Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

Syndax Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 05, 2025

Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 14, 2025

FDA Approvals Will Expand AML And cGVHD Treatment Options

Syndax Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 03, 2025

CEO & Director recently sold US$206k worth of stock

CEO & Director notifies of intention to sell stock

Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Consensus revenue estimates fall by 27%

Consensus revenue estimates fall by 18%

Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial

Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Consensus revenue estimates increase by 197%

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease